Novo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government will have an impact on its revenues next year.
Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’
Danish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Pharma – it has just agreed to acquire the biotech for $3.3 bill
Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light from the EMA's human medicines co
Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to b
Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis.